Brian Nussenbaum,
MD, FACS
Christy J. & Richard S. Hawes, III Professor,
Vice Chair for Clinical Affairs,
Patient Safety Officer
http://otocore.wustl.edu/
Contact:
(phone) 314-362-6599
(fax) 314-362-7522
Education:
B.A.: Mathematics, State University of New York , Binghamton, New York, 1990
Medical Degree: New York University School of Medicine, New York, New York, 1994
Elective Training: Otorhinolaryngic and Endocrine Pathology, Armed Forces Institute of Pathology, Washington, D.C., 1998
Residency: Otorhinolaryngology, University of Texas Southwestern, Dallas, Texas, 2000
Fellowship : Head and Neck Oncology, Microvascular Reconstructive Surgery, University of Michigan, Ann Arbor, Michigan, 2002
Research Area:
Head and Neck Oncology; Head and Neck Reconstruction; Tissue Engineering
Research Interest:
- The Bone Morphogenetic Protein (BMP) Signaling Pathway in Oral Cancer
Dr. Nussenbaum’s basic science research focuses on the bone morphogenetic protein (BMP) signaling pathway as it relates to oral cancer. Human recombinant BMP therapies have already been FDA-approved as an alternative to bone grafts for orthopaedic and orodental applications. The application of BMP therapies for bone regeneration after tumor resection is limited by the unknown effects of these morphogens on oral carcinoma cells. Studies are being performed to determine whether the BMP signaling pathway is functional in oral squamous cell carcinoma. Experiments are also being performed in vivo to determine the biologic effects of BMPs on oral cancer. This research will elucidate the safety of using BMPs for bone regeneration in oral cancer defects, and determine whether these proteins or inhibitors of these proteins may additionally have a therapeutic role in treating head and neck squamous cell carcinomas.
2. Craniofacial Bone Tissue Engineering
In addition to their important role during embryogenesis (bone, cartilage, nervous system, eyes, and kidneys in particular), BMP -2, -4, -6, -7, and -9 have strong osteoinductive activity. Human recombinant BMP-2 and -7 protein therapy have already been FDA approved as an alternative to bone grafts for limited orthopedic and orodental applications. The application of BMP therapies for bone tissue engineering in craniofacial or mandibular defects after tumor resection will be limited by the pre- or postoperative radiation that patients commonly need as part of cancer treatment. Dr. Nussenbaum, in collaboration with researchers at the University of Michigan, is also doing research investigating different practically applicable tissue engineering approaches for bone regeneration in wounds compromised by irradiation. Specifically, an ex vivo gene therapy approach with incorporating adjuvant therapies is being investigated, which has many advantages in this compromised bone defect setting.
Publications:
Selected Publications (Basic Science Research):
- Nussenbaum B, Krebsbach PH. The role of gene therapy for craniofacial and dental tissue engineering. Adv Drug Deliv Rev 2006; 58: 577-591.
- Nussenbaum B, Rutherford RB, Krebsbach PH. Bone regeneration in cranial defects previously treated with radiation. Laryngoscope 2005; 115: 1170-1177.
- Nussenbaum B, Teknos TN, Chepeha DB. Tissue engineering: the current status of this futuristic modality in head and neck reconstruction. Curr Opin Otolaryngol Head Neck Surg 2004; 12: 311-315.
- Nussenbaum B, Krebsbach PH. Practical matters in the application of tissue engineered products for skeletal regeneration in the head and neck region. Proceedings from Tissue Engineering in Musculoskeletal Clinical Practice Workshop sponsored by the American Association of Orthopedic Surgeons and the National Institutes of Health, edited by Sandell LJ and Grodzinsky AJ, pp. 151-159, 2004.
- Nussenbaum B, Rutherford RB, Teknos TN, Dornfeld KJ, Krebsbach PH. Ex vivo gene therapy for skeletal regeneration in cranial defects compromised by postoperative radiotherapy. Human Gene Therapy 2003; 14: 1107-1115.
- Sumer BD, Gastman BR, Gao F, Haughey BH, Paniello RC, Nussenbaum B. Caspase inhibition enhances ischemic tolerance of fasciocutaneous flaps. Laryngoscope 2005; 115: 1358-1361.
Selected Publications (Clinical Research):
- Chepeha DB, Teknos TE, Fung K, Shargorodsky J, Sacco AG, Nussenbaum B, Jones L, Eisbruch A, Bradford CR, Prince ME, Lee JS, Wolf GT, The lateral oromandibular defect: when is it appropriate to use a bridging reconstruction plate combined with a soft tissue revascularized flap? Accepted to Head Neck.
- Basu D, Siegel BA, McDonald DJ, Nussenbaum B. Detection of occult bone metastases from head and neck squamous cell carcinoma: impact of PET/CT imaging. Arch Otolaryngol Head Neck Surg 2007; 133: 801-805.
- Teknos TN, Nussenbaum B, Bradford CR, Prince ME, El-Kashlan H, Chepeha DB. Reconstruction of complex parotidectomy defects using the lateral arm free tissue transfer. Otolaryngol Head Neck Surg 2003; 129: 183-191.
- Schmalbach CE, Nussenbaum B, Rees R, Schwartz J, Johnson TM, Bradford CR. Reliability of sentinel lymph node mapping with biopsy for predicting regional spread of head and neck cutaneous melanoma. Arch Otolaryngol Head Neck Surg 2003; 129: 61-65.
- Myers LL, Nussenbaum B, Bradford CR, Teknos TN, Esclamado RM, Wolf GT. Paranasal sinus malignancies: An 18-year single institution experience. Laryngoscope 2002; 112: 1964-1969.
- Chepeha DB, Nussenbaum B, Bradford CR, Teknos TN. Leech therapy for patients with surgically unsalvageable venous obstruction after revascularized free tissue transfer. Arch Otolaryngol Head Neck Surg 2002; 128: 960-965.
- Nussenbaum B, Liu JH, Sinard RJ. Systematic management of chyle fistula: the Southwestern experience and a review of the literature. Otolaryngol Head Neck Surg 2000; 122: 31-38.
|